

# Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026

<https://marketpublishers.com/r/G0873620FADCEN.html>

Date: March 2020

Pages: 330

Price: US\$ 3,000.00 (Single User License)

ID: G0873620FADCEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026'  
Report Highlights:

Global Cancer Generics Market Trend Analysis

Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026

Global Generics Market Growth 2018-2026: > 130%

Global Cancer Generics Market Growth 2018-2026: 200%

Reimbursement Policies & the Coverage Strategies By Countries

Cancer Generic Drugs Availability, Dosage & Price Analysis By Segment

Comprehensive Insight On Cancer Generics Drugs: 43 Generics

Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality. The major advantage that is largely associated with the accelerated generics drug market is the fact that the development of the drug doesn't require prolonged period of time. The ease in developing the drug and the high adoption rate by

the patients contribute largely to the established markets of cancer generics.

'The Global Cancer Generic Drug Market To Witness Exponential Growth As Drug Sales Are Expected To Increase Its Sales Beyond US\$ 55 Billion By 2026'

It is well witnessed fact that the survival rate of the cancer patients have experienced a positive trail since the advent of the cancer generic drugs in the market. Patients and clinicians, whenever possible are more inclined towards the utilization of generic drugs in their treatment, as it is more segmented towards the patients that are not able to consume branded drugs, which however comprises of the maximum population around the globe. The necessity of generic drugs in the society and the upsurge it has been experiencing since its arrival at the global pharmaceutical landscape represents a stage of the market which is highly dominated by the cancer generics drugs.

Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive. The most important and the fundamental advantages that are received by the approach is that it provides the bioequivalent form of the original branded drug i.e. in same dosage, mode of administration and the effectiveness in a way cheaper price. Such advantages are making the whole percentage of patients with no or less hope towards a more suitable and decent method by providing a privileged from of treatment.

The increasing consumption of the generic drugs and the mounting trust of patient towards cancer generics drugs are going to play a very important role in the market expansion. A big contribution for the splendid market growth rate is also provided by the governing bodies of the respective country. The impositions made by the governing bodies for clinicians in dispensing generic drugs have caused an accelerated growth in the market size. The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

The research report "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe. The research report is a result of the extensive study conducted by analyzing the global companies for cancer generics. The opinions from the different generic drug companies have been gathered to successfully deliver the latest trends and opportunities and the future prospects on commercials for the

market of cancer generics.

## Contents

### **1. INTRODUCTION TO CANCER GENERICS**

- 1.1 Overview
- 1.2 The Growing Need for Cancer Generics over Branded Drugs
  - 1.2.1 Reduced Developmental Cost Leading to Cost-Efficient Cancer Generics
  - 1.2.2 Reduced Timeline Leading to Cost-Efficient Cancer Generics Development
  - 1.2.3 Cancer Generics Representing Same Effectiveness as of Branded Drugs

### **2. GLOBAL CANCER GENERICS MARKET TREND ANALYSIS**

- 2.1 Overview
- 2.2 Current Market Scenario
- 2.3 Cancer Generics Market Future Outlook

### **3. US - CURRENT MARKET STATUS OF CANCER GENERICS**

- 3.1 Significant Facts & Figures Prevailing Cancer Generics Market
- 3.2 US Cancer Generics Market Trends & Opportunities
  - 3.2.1 Guidelines, Policies & Procedures by the FDA for the US Market

### **4. JAPAN - CURRENT CANCER GENERICS MARKET INSIGHT**

- 4.1 Factors Propelling the Growth of Cancer Generics in Japan
- 4.2 Trends & Opportunities of Cancer Generics Market in Japan
  - 4.2.1 Cancer Generic Drugs Prescription & Dispensing

### **5. EUROPE - KEY ASSET TO CANCER GENERICS MARKET PROGRESSION**

- 5.1 Evaluation of Facts Associated with Cancer Generics Growth
- 5.2 Cancer Generics Market Current Trends & Opportunities
  - 5.2.1 Europe Government Regulations for Cancer Generics Market Progress
  - 5.2.2 Germany - Current Cancer Generics Market Trends & Opportunities
  - 5.2.3 France - Current Cancer Generics Market Trends & Opportunity
  - 5.2.4 UK - Current Cancer Generics Market Trends & Opportunities
  - 5.2.5 Belgium - Current Cancer Generics Market Trends & Opportunities
  - 5.2.6 Others - Current Cancer Generics Market Trends & Opportunities

## **6. CHINA - AS A EMERGED CANCER GENERIC MARKET IN ASIA**

- 6.1 Simulating Facts & Figures for Chinese Cancer Generics Market
- 6.2 Trends & Opportunities Linked with China's Cancer Generics Market
  - 6.2.1 Laws & Regulating Supporting Cancer Generics Market in China

## **7. INDIA - A MAJOR CONTRIBUTOR TO THE GLOBAL GENERICS MARKET**

- 7.1 Fact Sheets Related to Cancer Generics Growth in India
- 7.2 Trends & Opportunities for India's Cancer Generics Market
  - 7.2.1 Guidelines & Laws for Implementing Generic Drugs in India

## **8. SOUTH KOREA - CANCER GENERICS MARKET CURRENT INSIGHT**

- 8.1 Cancer Generics Drug Market Expansion Facts & Figures
- 8.2 Provoking Trends & Opportunities for South Korean Cancer Generics Market

## **9. RUSSIA - CANCER GENERICS MARKET SCENARIO**

- 9.1 Facts Encouraging the Current Market Situation in Russia
- 9.2 Trends & Opportunities Followed by Russian Cancer Generics Market
  - 9.2.1 Rules & Regulations Boosting the Current Market of Cancer Generics

## **10. REIMBURSEMENT POLICIES & THE COVERAGE STRATEGIES**

- 10.1 US
- 10.2 Europe
- 10.3 India
- 10.4 Japan
- 10.5 China
- 10.6 Russia

## **11. PRICE ANALYSIS FOR BRANDED DRUGS VS GENERIC DRUGS**

## **12. BREAST CANCER GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 12.1 Letrozole
- 12.2 Anastrozole

- 12.3 Exemestane
- 12.4 Epirubicine
- 12.5 Toremifene
- 12.6 Fulvestrant
- 12.7 Megestrol

### **13. COLORECTAL CANCER GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 13.1 Irinotecan
- 13.2 Oxaliplatin

### **14. LEUKEMIA GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 14.1 Clofarabin
- 14.2 Imatinib
- 14.3 Mercaptopurine
- 14.4 Idarubicin
- 14.5 Daunorubicin
- 14.6 Cytarabin

### **15. PROSTATE CANCER GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 15.1 Abiraterone
- 15.2 Bicalutamide
- 15.3 Nilutamide
- 15.4 Flutamide

### **16. SKIN CANCER GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 16.1 Imiquimod Topical Cream
- 16.2 Fluorouracil Topical

### **17. LUNG CANCER GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

- 17.1 Vinorelbine

## **18. BRAIN TUMOR GENERIC DRUGS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

18.1 Temozolomide

## **19. RENAL CELL CARCINOMA GENERIC DRUG - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

19.1 Temsirolimus

## **20. GENERIC DRUGS FOR MULTIPLE CANCERS - AVAILABILITY, DOSAGE & PRICE ANALYSIS**

20.1 Erlotinib

20.2 Dactinomycin

20.3 Ifosfamide

20.4 Romidepsin

20.5 Everolimus

20.6 Capecitabine

20.7 Gemcitabine

20.8 Paclitaxel

20.9 Fluorouracil

20.10 Docetaxel

20.11 Methotrexate

20.12 Cyclophosphamide

20.13 Vincristine

20.14 Etoposide

20.15 Mitoxantrone

20.16 Carmustine

20.17 Dacarbazine

20.18 Mitomycin

20.19 Bleomycin

## **21. GLOBAL CANCER GENERICS MARKET DYNAMICS**

21.1 Factors Favoring the Growth of Cancer Generics Market

21.2 Factors Restraining the Growth of Cancer Generics Market

22. Competitive Landscape

- 22.1 Teva Pharmaceuticals
- 22.2 Accord Healthcare
- 22.3 Amneal Pharmaceuticals
- 22.4 Mylan
- 22.5 Dr. Reddy Laboratories
- 22.6 Bedford Pharma
- 22.7 Hikma
- 22.8 Cipla
- 22.9 Shilpa Medicare
- 22.10 Fresenius Kabi
- 22.11 Zydus Pharmaceuticals
- 22.12 Neopharm
- 22.13 Netco
- 22.14 Mayne Pharma
- 22.15 Alvogen
- 22.16 Glenmark
- 22.17 HBT Labs
- 22.18 Gland
- 22.19 Qilu Pharmaceuticals
- 22.20 Akorn Pharmaceuticals
- 22.21 MSN Group
- 22.22 Wockhardt
- 22.23 Rising Pharma
- 22.24 Apotex
- 22.25 Taro Pharmaceuticals
- 22.26 Sun Pharma
- 22.27 Alkem Laboratories
- 22.28 Endo Pharma
- 22.29 Pfizer (Hospira)



## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Objectives of Cancer Generics for Cancer Patients
- Figure 1-2: Gleevec - Comparison between Branded & Generic Drug Price for 30 Tablets of 400 mg (US\$), January'2020
- Figure 1-3: Key Differences Between Branded & Generic Drugs
- Figure 1-4: Global - Cost of Branded Drug vs. Generic Drug Development, (US\$ Million)
- Figure 1-5: Cancer Generic vs. Branded Developmental Timeline
- Figure 1-6: Developmental Timeline for Branded Drug & Generic Drug (Years)
- Figure 2-1: Global –Pharmaceutical Market (US\$ Trillion), 2018 - 2026
- Figure 2-2: Global – Size of Total Cancer Market vs. Cancer Generics Market (US\$ Billion), 2018
- Figure 2-3: Global – Size of Total Cancer Market vs. Cancer Generics Market (%), 2018
- Figure 2-4: Global – Estimated Cancer Market vs. Cancer Generics Market (US\$ Billion), 2018 - 2026
- Figure 2-5: Global – Expected Generics Market Size (US\$ Billion), 2018 - 2025
- Figure 2-6: Global – Market Size of Cancer Generics (US\$ Billion), 2018 & 2026
- Figure 2-7: Global – Estimated Market Size of Cancer Generics (US\$ Billion), 2018 – 2026
- Figure 3-1: US – Total Cancer Deaths, 2018 & 2019
- Figure 3-2: US – Cancer Mortality Rate by Gender per 100,000 Person, 2018
- Figure 3-3: US – Cancer Statistics of Children of age 0 – 9 Years, 2017
- Figure 3-4: US – National Expenditure for Cancer Care (US\$ Billion), 2015 & 2017
- Figure 3-5: US – Population Statistics (Million), 2018 & 2019
- Figure 3-6: US vs. ROW Population Statistics (%), 2019
- Figure 3-7: US – Prescription Share of Generic Drugs filled at less than US\$ 20 (%), 2018
- Figure 3-8: US – Average Branded & Generic Drug Copy (US\$), 2018
- Figure 3-9: US – Generic Medicine Utilization by Age (%), 2017
- Figure 3-10: US – Top Generic Drug Pharmaceutical Companies, 2019
- Figure 3-11: US – Expected Generic Drug Market Size (US\$ Billion), 2018 - 2025
- Figure 3-12: US – Market of Prescription Spending (%), 2017
- Figure 3-13: US – Minimum & Maximum Generic Drug Prescriptions out of every 10 Prescriptions, 2017
- Figure 4-1: Japan – Cancer Statistics (Million), 2018
- Figure 4-2: Japan – Population Statistics (Million), 2018 - 2020
- Figure 4-3: Japan vs. ROW Population Statistics (%), 2019

Figure 4-4: Japan – Expected Penetration of Generics Market in the Country (US\$ Billion%), 2017 & 2018

Figure 4-5: Japan – Top Cancer Generics Pharmaceuticals

Figure 4-6: Japan – Estimated Cancer Market Size (US\$ Million), 2018 - 2026

Figure 4-7: Japan – Expected Generic Market Size (US\$ Billion), 2018 - 2026

Figure 4-8: Japan – Market Representation by Generic Drugs (%), 2020

Figure 4-9: Total Cancer Drug Market Global vs. Japan Cancer Drug Market (US\$ Billion), 2019

Figure 4-10: Generics Drug Market - Global vs. Japan (US\$ Billion), 2019

Figure 5-1: Europe – Population Statistics (Million), 2017 - 2019

Figure 5-2: Europe – Population Statistics by Region (Million), 2020

Figure 5-3: Europe vs. ROW Population Statistics (%), 2019

Figure 5-4: Europe vs. Global Population (Million), 2018 & 2019

Figure 5-5: Europe – Cancer Statistics (Million), 2018

Figure 5-6: Europe – Pharmaceutical Sales (US\$ Billion), 2018 - 2020

Figure 5-7: Europe – Top Cancer Generics Pharmaceutical Companies

Figure 5-8: Germany – Population Statistics (Million), 2018 - 2020

Figure 5-9: Germany – Cancer Statistics (Million), 2018

Figure 5-10: Germany – Expected Total Pharmaceutical Market (US\$ Billion), 2018 - 2026

Figure 5-11: Germany – Expected Generics Market Size (US\$ Billion), 2018 – 2026

Figure 5-12: Germany – Penetration of Generics Market into Total Pharmaceutical Market (%), 2019

Figure 5-13: Germany – Driving Factors for Generics Market

Figure 5-14: France – Population Statistics (Million), 2017 - 2019

Figure 5-15: France – Cancer Statistics (Million), 2018

Figure 5-16: France – Expected Total Pharmaceutical Market (US\$ Billion), 2018 - 2026

Figure 5-17: France – Expected Generics Market Size (US\$ Billion), 2018 - 2026

Figure 5-18: UK – Population Statistics (Million), 2017 - 2019

Figure 5-19: UK – Cancer Statistics (Million), 2018

Figure 5-20: UK – Expected Pharmaceutical Market Size (US\$ Billion), 2018 - 2026

Figure 5-21: UK – Expected Number of Generic Subscriptions Fulfilled (Million), 2018 - 2026

Figure 5-22: Belgium – Estimated Pharmaceutical Market Size (US\$ Billion), 2018 - 2026

Figure 5-23: Belgium – Expected Generic Market (US\$ Million), 2018 - 2026

Figure 5-24: Belgium – Penetration of Generic Market in Total Pharmaceutical Market, 2019

Figure 6-1: China – Population Statistics (Million), 2016 - 2020

Figure 6-2: China vs. Global Population Statistics (%), 2019

Figure 6-3: China – Cancer Statistics (Million), 2018

Figure 6-4: China – Registered Drugs (%), 2019

Figure 6-5: China – Generic Drug Application Procedure

Figure 6-6: China – Top Pharmaceutical Companies

Figure 6-7: China – Expected Total Pharmaceutical Market (US\$ Billion), 2018 - 2025

Figure 6-8: China – Estimated Cancer Market Size (US\$ Million), 2018 - 2026

Figure 6-9: China – Estimated Generics Market Size (US\$ Billion), 2018 - 2026

Figure 6-10: China –Pharmaceutical Market vs. Generics Market (US\$ Billion), 2018 - 2026

Figure 7-1: India – Population Statistics (Million), 2017 - 2019

Figure 7-2: Total Population vs. Population of India (%), 2019

Figure 7-3: India – Cancer Statistics (Million), 2018

Figure 7-4: India – Expected Pharmaceutical Market Size (US\$ Billion), 2018 - 2026

Figure 7-5: India – Percentage of India's Pharmaceutical Market vs. Global, 2018

Figure 7-6: India – Expected Pharmaceutical Export Market (US\$ Billion), 2018 - 2025

Figure 7-7: India – Estimated Cancer Drug Market (US\$ Billion), 2018 - 2026

Figure 7-8: India – Top Generic Drug Pharmaceutical Companies

Figure 7-9: India – Expected Generic Market Size (US\$ Billion), 2018 – 2026

Figure 7-10: India – Exports of Generics (%), 2019

Figure 7-11: Ibrunat – Price of Branded Drug vs. Generic Drug (US\$), 2019

Figure 7-12: Hertab – Price of Branded Drug vs. Generic Drug (US\$), 2019

Figure 8-1: South Korea – Population Statistics (Million), 2017 - 2019

Figure 8-2: South Korea – Cancer Statistics (Million), 2018

Figure 8-3: South Korea – Countries Buying Korean Drugs (US\$ Million), 2018

Figure 8-4: South Korea – Top Generic Drug Pharmaceutical Companies

Figure 8-5: South Korea – Estimated Pharmaceutical Market (US\$ Billion), 2018 - 2026

Figure 8-6: South Korea – Cancer Drug Market Estimates (US\$ Billion), 2018 - 2026

Figure 8-7: South Korea – Expected Generics Market Size (US\$ Billion), 2018 - 2026

Figure 9-1: Russia – Population Statistics (Million), 2017 - 2019

Figure 9-2: Russia – Cancer Statistics (Million), 2018

Figure 9-3: Russia – Demographics of Cancer Deaths (Million), 2018 & 2035

Figure 9-4: Russia – Estimated Pharmaceutical Market Size (US\$ Billion), 2018 - 2026

Figure 9-5: Russia – Domestic vs. International Pharmaceutical Volume Share (%), 2019

Figure 9-6: Russia – Expected Domestic vs. International Pharmaceutical Value Share (%), 2019

Figure 9-7: Russia – Estimated Generics Drug Market (US\$ Billion), 2018 - 2026

Figure 9-8: Russia – Share of Generics in the Total Pharmaceutical Market (%), 2018

- Figure 9-9: Russia – Average Cost of Branded v/s Generic Drug (US\$), 2019
- Figure 9-10: Russia –Generic Drugs v/s Branded Drug Package Sales Volume (%), 2019
- Figure 10-1: South Korea – Population Enrolled vs. Not Enrolled under National Health Insurance, 2018
- Figure 10-2: South Korea – Population Enrolled vs. Not Enrolled under National Health Insurance (%), 2018
- Figure 11-1: Key Factors for Low Pricing of the Generic Drugs in the Market
- Figure 12-1: Letrozole – FDA & First Generic Approval Year
- Figure 12-2: Letrozole – Price for a Supply of 30 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-3: Letrozole – Price for a Supply of 50 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-4: Letrozole – Price for a Supply of 90 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-5: Letrozole – Price for a Supply of 1000 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-6: Letrozole – Price Comparison of 30 Tablets Supply of Branded & Generic Letrozole (US\$), 2020'January
- Figure 12-7: Letrozole – Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US\$), 2020'January
- Figure 12-8: Anastrozole - FDA & Generic Approval Year
- Figure 12-9: Anastrozole - Price for a Supply of 6 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-10: Anastrozole - Price for a Supply of 15 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-11: Anastrozole – Average Price for a Supply of 30 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-12: Anastrozole - Price for a Supply of 50 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-13: Anastrozole – Average Price for a Supply of 90 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-14: Anastrozole - Price for a Supply of 500 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-15: Anastrozole - Price for a Supply of 1000 Tablets & Price per Unit Tablet (US\$), 2020'January
- Figure 12-16: Anastrozole – Price Comparison of 30 Tablets Supply of Branded & Generic Anastrozole (US\$), 2020'January
- Figure 12-17: Letrozole – Daily, Monthly & Annual Treatment Cost for Breast Cancer

(US\$), 2020'January

Figure 12-18: Armidex – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US\$), 2020'January

Figure 12-19: Exemestane - FDA & First Generic Approval Year

Figure 12-20: Exemestane – Price Comparison of 30 Tablets of Branded & Generic Exemestane (US\$), 2020'January

Figure 12-21: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US\$), 2020'January

Figure 12-22: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US\$), 2020'January

Figure 12-23: Epirubicine - FDA & First Generic Approval Year

Figure 12-24: Epirubicine – Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US\$), January'2020

Figure 12-25: Epirubicine – Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US\$), January'2020

Figure 12-26: Ellence – Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US\$), January'2020

Figure 12-27: Ellence – Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US\$), January'2020

Figure 12-28: Epirubicine – Minimum & Maximum Duration of Breast Cancer Treatment (Weeks), January'2020

Figure 12-29: Epirubicine – Average Cost of Single Treatment Cycle and Full Treatment using 120/m<sup>2</sup> Dose Regimen (US\$), January'2020

Figure 12-30: Ellence – Average Cost of Single Treatment Cycle and Full Treatment using 120/m<sup>2</sup> Dose Regimen (US\$), January'2020

Figure 12-31: Epirubicine – Average Cost of Single Treatment Cycle and Full Treatment using 100/m<sup>2</sup> Dose Regimen (US\$), January'2020

Figure 12-32: Ellence – Average Cost of Single Treatment Cycle and Full Treatment using 100/m<sup>2</sup> Dose Regimen (US\$), January'2020

Figure 12-33: Toremifene - FDA & First Generic Approval Year

Figure 12-34: Toremifene – Price Comparison of 30 Tablets of Branded & Generic Toremifene (US\$), 2020'January

Figure 12-35: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US\$), 2020'January

Figure 12-36: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US\$), 2020'January

Figure 12-37: Fulvestrant - FDA & First Generic Approval Year

Figure 12-38: Fulvestrant – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US\$), January'2020

Figure 12-39: Faslodex – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US\$), January'2020

Figure 12-40: Fulvestrant – Number of Dose Administration in Initial & Subsequent Months, January'2020

Figure 12-41: Fulvestrant – Treatment Cost of Initial & Subsequent Months (US\$), January'2020

Figure 12-42: Fulvestrant – Treatment Cost of Initial & Subsequent Year (US\$), January'2020

Figure 12-43: Faslodex – Treatment Cost of Initial & Subsequent Months (US\$), January'2020

Figure 12-44: Faslodex – Treatment Cost of Initial & Subsequent Year (US\$), January'2020

Figure 12-45: Megastrol - FDA & Generic Approval Year

Figure 12-46: Megastrol – Price for Various Supplies of 40mg/ml Oral Suspension (US\$), January'2020

Figure 12-47: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US\$), January'2020

Figure 12-48: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US\$), January'2020

Figure 12-49: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US\$), January'2020

Figure 12-50: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US\$), January'2020

Figure 12-51: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US\$), 2020'January

Figure 12-52: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US\$), 2020'January

Figure 13-1: Irinotecan - FDA & First Generic Approval Year

Figure 13-2: Irinotecan – Price Comparison of 2ml Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 13-3: Irinotecan – Price Comparison of 5 ml Intravenous Branded & Generic Solution (US\$), 2020'January

Figure 13-4: Irinotecan – Price of 25ml & Price per ml of Intravenous Solution (US\$), 2020'January

Figure 13-5: Captostar – Price of 15ml & Price per ml of Intravenous Solution (US\$), 2020'January

Figure 13-6: Irinotecan – Minimum & Maximum Duration of Treatment Cycle (Weeks), January '2020

Figure 13-7: Irinotecan – Cost of Single Treatment Cycle using Branded & Generic

Irinotecan Intravenous Solution (US\$), January '2020

Figure 13-8: Oxaliplatin - FDA & First Generic Approval Year

Figure 13-9: Oxaliplatin – Price of 50 mg & 100 mg Intravenous Powder for Injection (US\$), 2020'January

Figure 13-10: Oxaliplatin – Price of 10ml & 1ml Intravenous Solution for Injection (US\$), 2020'January

Figure 13-11: Oxaliplatin – Price of 20ml, 100ml & 200 ml Intravenous Solution for Injection (US\$), 2020'January

Figure 13-12: Eloxatin – Price of 10ml & 1ml Intravenous Solution for Injection (US\$), 2020'January

Figure 13-13: Eloxatin – Price of 20ml & 1ml Intravenous Solution for Injection (US\$), 2020'January

Figure 13-14: Oxaplatin – Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020'January

Figure 13-15: Oxaplatin Powder – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US\$), 2020'January

Figure 13-16: Oxaplatin Solution – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US\$), 2020'January

Figure 13-17: Eloxatin – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US\$), 2020'January

Figure 14-1: Clofarabin - FDA & First Generic Approval Year

Figure 14-2: Clofarabin - Price Comparison of 20 ml Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 14-3: Clofrabin – Average cost of Single Treatment Cycle using Branded & Generic Solution (US\$), january'2020

Figure 14-4: Imatinib - FDA & First Generic Approval Year

Figure 14-5: Imatinib – Price of 20 Tablets & Price per Unit of 100mg Tablet (US\$), 2020'January

Figure 14-6: Imatinib – Price of 30 Tablets & Price per Unit of 100mg Tablet (US\$), 2020'January

Figure 14-7: Imatinib – Average Price of 90 Tablets & Price per Unit of 100mg Tablet (US\$), 2020'January

Figure 14-8: Imatinib – Average Price of 20 & 30 Tablets Supply of 400mg Tablet (US\$), 2020'January

Figure 14-9: Gleevec – Price of 90 Tablets & Price per Unit of 100mg Tablet (US\$), 2020'January

Figure 14-10: Gleevec – Price of 30 Tablets & Price per Unit of 400mg Tablet (US\$), 2020'January

Figure 14-11: Imatinib – Dose in Chronic & Accelerated Phase of Mylogenous Leukemia

(mg), January'2020

Figure 14-12: Imatinib – Chronic Phase Treatment Cost Comparison using Branded & Generic Tablet (US\$), January'2020

Figure 14-13: Imatinib – Accelerated Phase Treatment Cost Comparison using Branded & Generic Tablet (US\$), January'2020

Figure 14-14: Mercaptopurine - FDA & First Generic Approval Year

Figure 14-15: Mercaptopurine – Price of 25 Tablets & Price per Unit of 50mg Tablet (US\$), 2020'January

Figure 14-16: Mercaptopurine – Price of 250 Tablets & Price per Unit of 50mg Tablet (US\$), 2020'January

Figure 14-17: Mercaptopurine – Daily, Monthly & Annual Treatment Cost of ALL (US\$), January'2020

Figure 14-18: Idarubicin - FDA & First Generic Approval Year

Figure 14-19: Idarubicine – Price Comparison of 5ml Intravenous Branded & Generic Solution (US\$), 2020'January

Figure 14-20: Idarubicine – Price Comparison of 10ml Intravenous Branded & Generic Solution (US\$), 2020'January

Figure 14-21: Idarubicine – Price Comparison of 20ml Intravenous Branded & Generic Solution (US\$), 2020'January

Figure 14-22: Idarubicin – Dially & Maximum Cumulative Lifetime Dose (mg/m<sup>2</sup>), January'2020

Figure 14-23: Idarubicin – Comparison of Dially & Full Treatment Cost using Branded & Generic Tablet (US\$), January'2020

Figure 14-24: Cerubidine - FDA & First Generic Approval Year

Figure 14-25: Daunorubicin – Price of 10 ml Supply & Price per ml of Intravenous Solution (US\$), 2020'February

Figure 14-26: Daunorubicin – Price of 40 ml Supply & Price per ml of Intravenous Solution (US\$), 2020'February

Figure 14-27: Daunorubicin – Number of Dose Administration in Initial & Subsequent Cycle for Acute Nonlymphocytic Leukemia, 2020'February

Figure 14-28: Daunorubicin – Adult Dose for Acute Nonlymphocytic Leukemia by Age Group (mg/m<sup>2</sup>), 2020'February

Figure 14-29: Daunorubicin – Cost of Single Dose for Nonlymphocytic Leukemia by Age Group (US\$), 2020'February

Figure 14-30: Cytarabin – Price for 25ml & 50ml Supply of 20mg/ml Intravenous Solution (US\$), 2020'February

Figure 14-31 Cytarabin – Price for 20ml Supply of 100mg/ml Intravenous Solution (US\$), 2020'February

Figure 14-32: Cytarabin – Average Minimum & Maximum Cost of Daily Treatment of



Acute Nonlymphocytic Leukemia (US\$), 2020'February

Figure 14-33: Cytarabin – Average Daily & Full Treatment Cost in Initial Phase of Meningeal Leukemia (US\$), 2020'February

Figure 15-1: Abiraterone - FDA & First Generic Approval Year

Figure 15-2: Aberaterone – Price of 30 Tablets & Price per unit of 250mg Tablet (US\$), 2020'January

Figure 15-3: Aberaterone – Price of 120 Tablets & Price per Unit of 250mg Tablet (US\$), 2020'January

Figure 15-4: Zytiga – Price of 120 Tablets & Price per unit of 250mg Tablet (US\$), 2020'January

Figure 15-5: Zytiga – Price of 60 Tablets & Price per Unit of 500mg Tablet (US\$), 2020'January

Figure 15-6: Abiraterone – Treatment Cost Comparison of Metastatic High-risk CSPC using Branded & Generic Tablet (US\$), January'2020

Figure 15-7: Abiraterone – Treatment Cost Comparison of Metastatic CSPC using Branded & Generic Tablet (US\$), January'2020

Figure 15-8: Bicalutamide - FDA & First Generic Approval Year

Figure 15-9: Bicalutamide - Price Comparison of 30 Tablets of Branded & Generic Bicalutamide (US\$), 2020'January

Figure 15-10: Bicalutamide – Price of 100 Tablets & Price per Unit of 50mg Tablet (US\$), 2020'January

Figure 15-11: Bicalutamide – Price of 500 Tablets & Price per Unit of 50mg Tablet (US\$), 2020'January

Figure 15-12: Bicalutamide – Treatment Cost Comparison of Prostate Cancer using Branded & Generic Tablet (US\$), January'2020

Figure 15-13: Nilutamide - FDA & First Generic Approval Year

Figure 15-14: Nilutamide - Price Comparison of 30 Tablets of Branded & Generic Nilutamide (US\$), 2020'January

Figure 15-15: Nilutamide – Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day), January'2020

Figure 15-16: Nilutamide – Comparison of Initial Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US\$), January'2020

Figure 15-17: Nilutamide – Comparison of Maintenance Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US\$), January'2020

Figure 15-18: Flutamide - FDA & First Generic Approval Year

Figure 15-19: Flutamide - Price Comparison of 180 Capsules of Branded & Generic Flutamide (US\$), 2020'January

Figure 15-20: Flutamide – Comparison of Daily, Monthly & Annual Treatment of Prostate Cancer using Branded & Generic Capsule (US\$), January'2020

Figure 16-1: Aldara - FDA & First Generic Approval Year

Figure 16-2: Imiquimod – Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US\$), 2020'January

Figure 16-3: Imiquimod – Price for a Supply of 24 Creams & Price per Unit of 5% Topical Cream (US\$), 2020'January

Figure 16-4: Aldara – Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US\$), 2020'January

Figure 16-5: Imiquimod - Duration of Single Treatment Cycle & Full Treatment of Basal Cell Carcinoma (Weeks), January'2020

Figure 16-6: Imiquimod – Comparison of Single Treatment Cycle & Full Treatment using Branded & Generic 5% Cream (US\$), January'2020

Figure 16-7: Fluorouracil Cream - FDA & First Generic Approval Year

Figure 16-8: Fluorouracil Solution - FDA & First Generic Approval Year

Figure 16-9: Topical Fluorouracil - Price Comparison of 40gm Branded & Generic Cream (US\$), 2020'January

Figure 16-10: Topical Fluorouracil - Price of 10ml Supply & Price per ml of 5% Solution (US\$), 2020'January

Figure 16-11: Topical Fluorouracil – Minimum & Maximum Duration for Basal Cell Carcinoma Treatment (Weeks), 2020'January

Figure 17-1: Vinorelbine - FDA & First Generic Approval Year

Figure 17-2: Vinorelbine - Price Comparison of 5ml Supply of Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 17-3: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 17-4: Vinorelbine Monotherapy – Comparison of Treatment Cost of NSCLC using Branded & Generic Intravenous Solution (US\$), January'2020

Figure 17-5: Vinorelbine – Combinational Dose with 100mg/m<sup>2</sup> and 120 mg/m<sup>2</sup> Cisplatin (mg/m<sup>2</sup>), January'2020

Figure 18-1: Temozolomide Oral Capsule - FDA & First Generic Approval Year

Figure 18-2: Temozolomide - Price of Various Supplies of 5mg Capsule (US\$), 2020'January

Figure 18-3: Temozolomide - Price of Various Supplies of 20mg Capsule (US\$), 2020'January

Figure 18-4: Temozolomide - Price of Various Supplies of 100mg Capsule (US\$), 2020'January

Figure 18-5: Temozolomide - Price of Various Supplies of 100mg Capsule (US\$), 2020'January

Figure 18-6: Temozolomide - Price of 5 Capsules Supply of 180mg & 250mg Dose (US\$), 2020'January

Figure 18-7: Temodar - Price of 5 & 14 Capsules Supplies of Different Dose Regimen (US\$), 2020'January

Figure 18-8: Temozolomide – Initial & Maintenance Dose for Anaplastic Astrocytoma (mg/m<sup>2</sup>), 2020'January

Figure 18-9: Temozolomide – Anaplastic Astrocytoma Initial Treatment Cost Comparison using Branded & Generic Capsule (US\$), January'2020

Figure 18-10: Temozolomide – Anaplastic Astrocytoma Maintenance Treatment Cost Comparison using Branded & Generic Capsule (US\$), January'2020

Figure 18-11: Temozolomide – Glioblastoma Multiforme Treatment Cost Comparison using Branded & Generic Capsule (US\$), January'2020

Figure 19-1: Temsirolimus - FDA & First Generic Approval Year

Figure 19-2: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 19-3: Temsirolimus– Comparison of Treatment Cost of Renal Cell Carcinoma using Branded & Generic Intravenous Solution (US\$), January'2020

Figure 20-1: Erlotinib - FDA & First Generic Approval Year

Figure 20-2: Erlotinib – Price of 20 & 30 Tablets Supply of 25mg Dose (US\$), 2020'January

Figure 20-3: Erlotinib – Price of 20 & 30 Tablets Supply of 100mg Dose (US\$), 2020'January

Figure 20-4: Erlotinib – Price of 20 & 30 Tablets Supply of 150mg Dose (US\$), 2020'January

Figure 20-5: Tarceva – Price for 30 Tablets Supply of 25mg, 100mg & 150mg (US\$), 2020'January

Figure 20-6: Erlotinib – Comparison of Treatment Cost of NSCLC using Branded & Generic Tablet (US\$), January'2020

Figure 20-7: Erlotinib – Comparison of Treatment Cost of Pancreatic cancer using Branded & Generic Tablet (US\$), January'2020

Figure 20-8: Dactinomycin - FDA & First Generic Approval Year

Figure 20-9: Dactinomycin – Price for a Supply 12 and Price for Single Powder for Injection (US\$), 2020'January

Figure 20-10: Dactinomycin - Price Comparison of 0.5mg Branded & Generic Powder for Injection (US\$), 2020'January

Figure 20-11: Dactinomycin – Cost Comparison of Single Treatment Cycle of Wilm's Tumor using Branded & Generic Powder for Injection (US\$), 2020'January

Figure 20-12: Dactinomycin – Cost Comparison of Testicular Cancer Treatment using Branded & Generic Dactinomycin (US\$), January'2020

Figure 20-13: Dactinomycin – Treatment Cost Comparison Lower Extremity Solid Tumor using Branded & Generic Powder for Injection (US\$), 2020'January

Figure 20-14: Ifosfamide - FDA & First Generic Approval Year

Figure 20-15: Ifosfamide - Price Comparison of 1gm & 3gm Supply of Branded & Generic Powder for Injection (US\$), 2020'January

Figure 20-16: Ifosfamide – Price for a Supply 20ml & 60ml Intravenous Solution for Injection (US\$), 2020'January

Figure 20-17: Ifosfamide – Treatment Cost Comparison of Branded & Generic Powder fo Injection (US\$), January'2020

Figure 20-18: Istodax - FDA Approval & Patent Expiration Year

Figure 20-19: Romidepsin - Price Comparison of 10mg Branded & Generic Powder for Injection (US\$), 2020'January

Figure 20-20: Remidepsin – Treatment Cost Comparison of Branded & Generic Dactinomycin (US\$), January'2020

Figure 20-21: Afinitor - FDA & First Generic Approval Year

Figure 20-22: Evrolimus - Price of 28 Tablets Supplies of Various Dose Regimen (US\$), 2020'January

Figure 20-23: Afinitor - Price of 28 Tablets Supplies of Various Dose Regimen (US\$), 2020'January

Figure 20-24: Evrolimus – Treatment Cost Comparison of Various Cancers using Branded & Generic Tablet (US\$), January'2020

Figure 20-25: Capecitabine - FDA & First Generic Approval Year

Figure 20-26: Capecitabine – Average Price for a Supply of 60 Tablets & Price per Unit of 150mg Tablet (US\$), 2020'January

Figure 20-27: Capecitabine – Average Price for a Supply of 20 Tablets & Price per Unit of 500mg Tablet (US\$), 2020'January

Figure 20-28: Capecitabine – Price for a Supply of 30 Tablets & Price per Unit of 500mg Tablet (US\$), 2020'January

Figure 20-29: Capecitabine – Average Price for a Supply of 120 Tablets & Price per Unit of 500mg Tablet (US\$), 2020'January

Figure 20-30: Capecitabine – Price Comparison of 60 Tablets Supply of 150mg Branded & Generic Capecitabine (US\$), 2020'January

Figure 20-31: Capecitabine – Price Comparison of 120 Tablets Supply of 500mg Branded & Generic Capecitabine (US\$), 2020'January

Figure 20-32: Capecitabine – Duration of Treatment & Rest Phase in Single Treatment Cycle (Weeks), 2020'January

Figure 20-33: Capecitabine – Comparison of Treatment Cost of Breast Cancer using Branded & Generic Tablet (US\$), January'2020

Figure 20-34: Gemcitabine - FDA & First Generic Approval Year

Figure 20-35: Gemcitabine – Average Price of 200mg, 1gm & 2gm Powder for Injection (US\$), 2020'January

Figure 20-36: Gemzar – Average Price of 200mg & 1gm Powder for Injection (US\$), 2020'January

Figure 20-37: Gemcitabine – Average Price for Supply of 5.26ml, 26.3ml & 52.6 ml Solution for Injection of 38mg/ml (US\$), 2020'January

Figure 20-38: Gemcitabine – Average Price of 2ml, 10ml, 15ml & 20ml Intravenous Solution (US\$), 2020'January

Figure 20-39: Gemcitabine – Treatment Cost Comparison of Ovarian Cancer using Branded & Generic Solution (US\$), January'2020

Figure 20-40 Gemcitabine – Treatment Cost Comparison of NSCLC & Breast Cancer using Branded & Generic Solution (US\$), January'2020

Figure 20-41: Taxol - FDA & First Generic Approval Year

Figure 20-42: Paclitaxel - Average Price Various Supplies of Intravenous Solution for Injection (US\$), 2020'January

Figure 20-43: Paclitaxel – Dose for Treatment of Breast Cancer, NSCLC & Ovarian Cancer (Mg/m<sup>2</sup>/3 Weeks), 2020'February

Figure 20-44: Paclitaxel – Average Cost of single Dose & Annual Treatment of Breast Cancer (US\$), 2020'February

Figure 20-45: Paclitaxel – Average Cost of Single Dose & Full Treatment of Adjuvant Breast Cancer (US\$), 2020'February

Figure 20-46: Adrucil - FDA & First Generic Approval Year

Figure 20-47: Fluorouracil – Average Price of various Supplies of Intravenous Solution (US\$), 2020'January

Figure 20-48: Adrucil – Average Price of various Supplies of Intravenous Solution (US\$), 2020'January

Figure 20-49: Fluorouracil – Duration of Single Treatment cycle & Full Treatment of Breast Cancer (Weeks), 2020'January

Figure 20-50: Fluorouracil – Treatment Cost Comparison of Breast Cancer using Branded & Generic Intravenous Solution (US\$), 2020'January

Figure 20-51: Fluorouracil – Branded v/s Generic Initial Day Treatment Cost Comparison of Colorectal Cancer (US\$), 2020'January

Figure 20-52: Fluorouracil – Branded v/s Generic Subsequent Treatment Cycle Cost Comparison of Colorectal Cancer (US\$), 2020'January

Figure 20-53: Docetaxel - FDA & First Generic Approval Year

Figure 20-54: Docetaxel – Average Price of Various Supplies of Intravenous Solution of 10mg/ml Dose (US\$), 2020'February

Figure 20-55: Docetaxel – Average Price of various Supplies of Intravenous Solution of 20mg/ml Dose (US\$), 2020'February

Figure 20-56: Taxotere – Average Price for 1ml & 4 ml Supplies of Intravenous Solution (US\$), 2020'February

- Figure 20-57: Docetaxel – Treatment Cost Comparison of Branded & Generic Drug for Prostate Cancer & NSCLA (US\$), 2020'February
- Figure 20-58: Docetaxel Combination – Duration of Single Treatment Cycle & Full Treatment of Breast Cancer (Weeks), 2020'February
- Figure 20-59: Docetaxel – Treatment Cost Comparison of Branded & Generic Drug for Breast Cancer Management (US\$), 2020'February
- Figure 20-60: Methotrexate – Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US\$), 2020'February
- Figure 20-61: Methotrexate – Average Price of Different Supplies of Oral Tablet (US\$), 2020'February
- Figure 20-62: Methotrexate – Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), 2020'February
- Figure 20-63: Methotrexate – Single Treatment Cycle Cost in Initial & Maintenance Phase (US\$), 2020'February
- Figure 20-64: Methotrexate – Minimum & Maximum Treatment Cost of Initial Phase of ALL (US\$), 2020'February
- Figure 20-65: Methotrexate – Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), 2020'February
- Figure 20-66: Methotrexate – Minimum & Maximum Treatment Cost of Single Day (US\$), 2020'February
- Figure 20-67: Methotrexate – Minimum & Maximum Cost of Single Treatment Cycle (US\$), 2020'February
- Figure 20-68: Cyclophosphamide – Average Price for 1gm, 2gm & 500mg Powder for Injection (US\$), 2020'February
- Figure 20-69: Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US\$), 2020'February
- Figure 20-70: Cyclophosphamide IV Solution – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US\$), 2020'February
- Figure 20-71: Cyclophosphamide Capsule – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US\$), 2020'February
- Figure 20-72: Vincristine – Average Price for 1ml & 2ml Intravenous Solution (US\$), 2020'February
- Figure 20-73: Vincristine – Average Cost of Single Cycle, Monthly & Annual Treatment (US\$), February'2020
- Figure 20-74: Vincristine – Minimum & Maximum Pediatric Dose (mg/m<sup>2</sup>), February'2020
- Figure 20-75: Etoposide - FDA & First Generic Approval Year
- Figure 20-76: Etoposide – Price for a Supply of 5 ml, 25 ml & 50 ml Supply of Intravenous Solution (US\$), February'2020

Figure 20-77: Etoposide – Price for a Supply of 20 Tablets & Price per Unit of 50 mg Tablet (US\$), February'2020

Figure 20-78: Etoposide – Minimum & Maximum Duration of Single Treatment Cycle of SCLC (Weeks), February'2020

Figure 20-79: Etoposide – Average Cost of Daily Treatment & One Treatment Cycle of SCLC (US\$), February'2020

Figure 20-80: Etoposide – Minimum & Maximum Cost of Single Treatment Cycle of Testicular Cancer (US\$), February'2020

Figure 20-81: Mitoxantrone - FDA & First Generic Approval Year

Figure 20-82: Mitoxantrone – Price for a Supply of 10 ml, 12.5 ml & 15 ml Supply of Intravenous Solution (US\$), February'2020

Figure 20-83: Mitoxantrone – Average Cost of Single Treatment Cycle & Annual Treatment of Prostate Cancer (US\$), February'2020

Figure 20-84: Mitoxantrone – Average Cost of Induction & Consolidation Phase for Acute Non-Lymphocytic Leukemia (US\$), February'2020

Figure 20-85: Carmustine - FDA & First Generic Approval Year

Figure 20-86: Carmustine – Branded v/s Generic Price Comparison of 100mg Dose (US\$), February'2020

Figure 20-87: Etoposide – Minimum & Maximum Cost of Single Treatment Cycle (US\$), February'2020

Figure 20-88: BiCNU – Minimum & Maximum Cost of Single Treatment Cycle (US\$), February'2020

Figure 20-89: Dacarbazine - FDA & First Generic Approval Year

Figure 20-90: Dacarbazine – Price for a Supply of 10 & Price per Unit of 100 mg Powder for Injection (US\$), February'2020

Figure 20-91: Dacarbazine – Price for a Supply of 20 & Price per Unit of 200 mg Powder for Injection (US\$), February'2020

Figure 20-92: Dacarbazine – Minimum & Maximum Dose for Malignant Melanoma (mg/m<sup>2</sup>/day), February'2020

Figure 20-93: Dacarbazine – Minimum & Maximum Cost of One Treatment Cycle for Malignant Melanoma (US\$), February'2020

Figure 20-94: Dacarbazine – Cost of Single Dose & Single Treatment Cycle for Malignant Melanoma (US\$), February'2020

Figure 20-95: Mitomycin - FDA & First Generic Approval Year

Figure 20-96: Mitomycin – Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US\$), February'2020

Figure 20-97: Mutamycin – Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US\$), February'2020

Figure 20-98: Mitomycin – Minimum & Maximum Duration of Single Treatment Cycle

(Weeks), February'2020

Figure 20-99: Mitomycin – Branded v/s Generic Cost Comparison of Single Treatment Cycle (US\$), February'2020

Figure 20-100: Bleomycin - FDA & First Generic Approval Year

Figure 20-101: Bleomycin – Price for Supply of Single 15 Units & 30 Units Powder for Injection (US\$), February'2020

Figure 20-102: Bleomycin – Minimum & Maximum Cost for Single Once a Week Treatment Cycle (US\$), February'2020

Figure 20-103: Bleomycin – Minimum & Maximum Cost for Single Twice a Week Treatment Cycle (US\$), February'2020



## I would like to order

Product name: Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026

Product link: <https://marketpublishers.com/r/G0873620FADCEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0873620FADCEN.html>